LLY Chief ExecutiveWhat David A. Ricks says in public, and what their own SEC filings show they own.
Chair & CEO · Eli Lilly and Company
CEO since 2017. 25+ year Lilly veteran. Led operations in Canada and China, ran Lilly USA and Bio-Medicines. Purdue BS, Indiana MBA.
Ricks owns about 0% of Eli Lilly and Company, worth $814.6M at the last close.
Score = stake band (35) + founder (15) + tenure (10) + track record (15) + 12-month direction (−10…15) + filing discipline (10). Every input links to a filing or to the career file; the bands are ours.
Dots mark the months the activity below moved the line. Hover one for the filing.
| Security | Held via | Shares |
|---|---|---|
| Common Stock | Direct | 571,715 |
| Common Stock | David A. Ricks SLAT | 68,656 |
| Common Stock | David A. Ricks 2022 GRAT | 54,117 |
| Common Stock | 401(k) | 7,307 |
| Common Stock | David A. Ricks 2025 GRAT | 6,685 |
| Common Stock | Trust | 300 |
| Reported as of 2026-02-09 | 708,781 | |
| Date | Type | What happened | Shares | Price | Value | Note |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Award | Grant or award | +38,913 | $1,044.69 | $40.7M | |
| Feb 1, 2026 | Exercise | Option or RSU conversion | +31,932 | — | — | |
| Feb 1, 2026 | Tax | Shares withheld for tax | −14,296 | $1,037.20 | $14.8M | |
| Nov 10, 2025 | Gift | Gift | −24,750 | — | — |
| Company | Role | Reported | Beneficial | % of class |
|---|---|---|---|---|
| LLY ELI LILLY & Co This page | President, Chair, and CEO | 708,781 2026-02-09 |
— | — |
| ADBE ADOBE INC. | Director | 20,430 2026-06-25 |
— | — |
Reported is every lot on the person's own Forms 3, 4 and 5 — direct and through trusts. Beneficial is the figure stated on the latest Schedule 13D/G cover page, which can exclude shares the person disclaims and include options exercisable within 60 days, so the two are never added together.
65 filings under CIK 0001538604 · captured 2026-09-05 · All filings on EDGAR ↗
9 recorded appearances
Ricks said Lilly is 'pleased but not satisfied' after a Q2 beat and a raised full-year sales outlook, and argued oral GLP-1 therapies are expanding the addressable market rather than cannibalising injectables. He also addressed US drug-pricing policy.
Watch or read →
Ricks argued with Scott Galloway that GLP-1s change the economics of obesity treatment for the whole US health system, and criticised how the American insurance and pricing structure blocks access.
Watch or read →
With Woodline's Mike Rockefeller, Ricks laid out how Lilly balances its internal R&D engine against externally sourced innovation via acquisitions and partnerships, and how it compressed traditional development timelines.
Watch or read →
Ricks explained the science Lilly is pursuing to improve the GLP-1 class, and pushed back on AI hype in drug discovery — saying today's models are 'not particularly good' at solving core biology and chemistry problems.
Watch or read →
On stage with Jensen Huang, Ricks detailed Lilly's plan to build what the companies call the largest dedicated on-premises biology supercomputer, in Indianapolis, plus a joint co-innovation lab.
Watch or read →
Ricks discussed Lilly's path to a trillion-dollar market value, the launch of its oral obesity pill and the near-term pipeline.
Watch or read →
A long-form conversation with John and Patrick Collison on the economics of drug development — why capital allocation, manufacturing scale and pricing structure, not just science, determine which medicines get built.
Watch or read →
A moderated address on the global transformation of health care, covering chronic disease management, US manufacturing investment and pharma policy.
Watch or read →
Ricks walked through how Lilly discovered the GLP-1 weight-loss effect, the counterfeit-product problem sourced from China, GLP-1 pricing, and early signals on addiction and mental-health indications.
Watch or read →
